College Directory
< Back

Holly Hagan,

PhD, MPH, RN
Professor
726 Broadway, 10th Floor
New York, NY 10003
Phone: 
212-998-5221
Fax: 
212-995-3143
Email: 
hh50@nyu.edu
Areas of Specialization 

Epidemiology, infectious diseases, viral hepatitis, HIV, substance abuse, research methods, health disparities, systematic reviews, meta-analyses

Education 
PhD, 1997, University of Washington
MPH, 1987, University of Massachusetts, Amherst
RN, 1981, Seattle Central College
BA, 1975, The Evergreen State College
Professional Overview 
Dr. Hagan is an infectious disease epidemiologist and an expert in the infectious disease consequences of illicit drug use. She has gained an international reputation from her studies of hepatitis C virus infection in people who inject drugs, and her work on the etiology, epidemiology and prevention of HCV has informed harm reduction practices in the US and abroad. Dr. Hagan served on the Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis in the United States, and has been a chartered member of NIH AIDS-related study sections since 1999. She is Director of the Interdisciplinary Research Methods Core in the Center for Drug Use and HIV Research within NYU College of Nursing.
Licensure 
Registered Nurse, Washington State (inactive)
Professional Membership 
American Association for the Study of Liver Disease
American Public Health Association
International AIDS Society
International Harm Reduction Association
North American Syringe Exchange Network, Board Member
Society for Epidemiologic Research
Teaching 
NURSE-GN 3353 Knowledge Appraisal and Development
NURSE-GN 3400 PhD Advisement

PhD candidacy and dissertation advisement

Current Research Projects
Multiple HIV Prevention Packages for IDUs in Estonia
National Institute of Allergy and Infectious Diseases
Beth Israel Medical Center
Infectious Disease and Global Health

Multiple HIV Prevention Packages for IDUs in Estonia

Peer-Driven Intervention to Seek, Test and Treat Heterosexuals at High Risk for HIV
National Institute on Drug Abuse, National Institutes of Health (NIH)
Marya V. Gwadz
PhD, Senior Research Scientist, Deputy Director, Center for Drug Use and HIV Research (CDUHR), marya.gwadz@nyu.edu
Infectious Disease and Global Health

This project will evaluate the efficacy of a peer-driven intervention to seek out heterosexuals at high risk for HIV but who do not know they have HIV, test them, and link them to care if found to be HIV-infected.

Publications
Hagan H., Pouget E.R., & Des Jarlais D.C. (2011). A systematic review and meta-analysis of interventions to prevent hepatitis C virus seroconversion in people who inject drugs. Journal of Infectious Diseases, 204, 74-83. 10.1093/infdis/jir196.
Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak,D., & Degenhardt, L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet, 378, 571-583. 10.1016/S0140-6736(11)61097-0.
Hagan, H., Pouget, E.R., Williams, I.T., Garfein, R.L., Strathdee, S.A., Hudson, S. M., Latka, M.H., & Ouellet, L.J. (2010). Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Journal of Infectious Diseases, 201, 378-385. 10.1086/649783.
Hagan, H., Jenness, S.M., Wendel, T., Murrill, C.R., Neaigus, A., Gelpi-Acosta, C. (2010). Herpes simplex virus type 2 associated with HIV infection among New York heterosexuals living in high-risk areas. International Journal of STD & AIDS, 21, 580-583. 10.1258/ijsa.2010.010137.
Hagan, H., Pouget, E.R., Des Jarlais. D.C., & Lelutiu-Weinberger, C. (2008). Meta-regression of hepatitis C virus (HCV) infection in relation to time since onset of illicit drug injection: The influence of time and place. American Journal of Epidemiology, 168, 1099-1109. 10.1093/aje/kwn237.
Hagan, H., Latka, M., Campbell, J.V., Golub, E.T., Garfein, R.S., Thomas, D.A., Kapadia, F., & Strathdee, S.A. (2006). Eligibility for treatment of hepatitis C virus infection among young injection drug users in three US cities. Clinical Infectious Diseases, 42, 669-672. 10.1086/499951.
Hagan, H., Thiede, H., Weiss, N.S., Hopkins, S.G., Duchin, J., & Alexander, E.R. (2001). Sharing of drug preparation equipment associated with hepatitis C virus seroconversion in drug injectors. American Journal of Public Health, 91, 42-46. PMCID: PMC1446500.
Hagan, H., Des Jarlais, D.C., Friedman, S.R., Purchase, D., & Alter, M.J. (1995). Reduced risk of hepatitis B and hepatitis C in injecting drug users participating in the Tacoma syringe exchange program. American Journal of Public Health, 85, 1531-1537. PMCID: PMC1615682.
Back to top